Acrux Limited
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ACR.AX | FBIO | ACXP | CANF | PHRM.CN | DARE | |
|---|---|---|---|---|---|---|
| Market cap | 6.12M | 65.70M | 5.64M | 5.06M | 4.55M | 13.02M |
| P/E (TTM) | — | 0.7 | — | — | — | — |
| Forward P/E | — | -1.1 | -0.6 | -1.8 | -0.5 | -1.3 |
| Price/book | 3.3 | 0.4 | 0.6 | 0.7 | 7.1 | -17.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −33.33% | −21.77% | −80.19% | −80.71% | −52.38% | −63.43% |
| Today | 0.00% | +1.55% | +0.98% | +3.02% | −16.67% | +1.83% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All ACR.AX news ›Acrux Limited (ARUXF) Shareholder/Analyst Call Transcript
Acrux Limited (ARUXF) Shareholder/Analyst Call October 12, 2026 12:00 AM EDT John Warmbrunn - MD, CEO & DirectorJolanta Airey - Chief Medical OfficerFelicia Colagrande - Product Development & Technical Affairs Director Welcome to the Acrux…
Acrux secures FDA Phase 3 pathway approval
Assets related to this article Acrux (ASX:ACR) has secured a confirmed Phase 3 regulatory pathway from the U.S. Food and Drug Administration for its female testosterone metered-dose transdermal spray targeting hypoactive sexual desire…
Acrux Ltd Says FDA Clears Regulatory Pathway For Female Testosterone Mdts
TradingView Acrux Ltd Says FDA Clears Regulatory Pathway For Female Testosterone Mdts
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- grafa.com1
- seekingalpha.com1
- tradingview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.